Clinical Trials · NCT00976937

24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years

CompletedPhase 3Lixisenatide (Approved)
Phase
Phase 3
Recruitment status
Completed
Sponsor
Sanofi
Enrollment
319
Start date
Aug 2009
Locations
92 sites, 13 countries
Primary endpoint
Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than 7% and at Least 5% Weight Loss From Baseline at Week 24
View Lixisenatide compound reference